ASCO 2023

CDK4/6i in EBC: Have abema and ribo arrived in the early setting? Insights from North America and Europe

Discussions and controversies on social-media: what is the impact of science-twitter discussions on the everyday practice in oncology?

ADC revolution: How can the new results be integrated in clinical practice? Which studies are in sight and which ones do we need in the future?

Sonia trial: How does the new data change clinical practice - or does it at all? Insights from Italy, United States and Germany.

Expanding CDK4/6i therapy in EBC: How to select patients for the right therapy?

PART2: Trying to understand optimal therapy for pre-menopausal women - promising results, but still long way to go!

CDK4/6 inhibitors in EBC: Amazing data, but longer follow up needed!

PART1: How to de-escalate chemotherapy? What is the best strategy to identify patients who don´t need chemotherapy?

New data on Ribocilib in adjuvant setting EBC: What does it change immediately, what changes are expected in the future? Perspectives from Europe and Northern America

Chemotherapy de-escalation in HER2+ patients: Consequences of the PHERGain data on daily practice?!

Data from Meta-Analyses of almost 15k Patients: Who benefits from ovarian function suppression?

PHERGain opens the possibility to avoid chemotherapy in HER2+ breast cancer

More CDK4/6 options for EBC patients

Ribociclib has arrived in the adjuvant setting

TILs are prognostic but not predictive in HER2+ EBC

My EBC highlights from ASCO23

First data with adjuvant ribociclib

Ovarian function - Ovarian suppression not necessary in young patients?

Discussions on CDK4/6 inhibitors in EBC

Palbociclib after Palbociclib might not be the best option

Tumor-informed ctDNA likely prognostic for relapse in ER positive and HER2 negative EBC

From PENELOPE-B to SURVIVE

Analyses of ctDNA in PENELOPE-B: Test methods are increasingly accurate

Response adapted, chemotherapy-free option in HER2+ EBC

Another proof of efficacy of immunotherapy in advanced TNBC

SOC of ovarian ablation confirmed in meta-analysis.

Practice changing or not quite yet?

Chemo-immunotherapeutic signals especially in HER2low possibly predictive of chemotherapy response in EBC

Young patients benefit from ovarian suppression

White blood cells with increasing prognostic relevance? Data from the GeparNuevo Study

A challenge for clinical management

Checkpoint inhibition in endometrial cancer: new therapy algorithms needed

De-escalation of CT for early BC

10 years update on ShortHER

TILs in HER2+ disease - prognostic, but not enough to deescalate

1/3 of patients with HER2+ in future without chemotherapy?

TILs subtypes are associated with clinical features and prognosis in HR+/HER2- BC

Early follow-up shows clear benefit

Ribociclib improves iDFS

Can we preserve our patients form chemotherapy?

Tumor-informed ctDNA wahrscheinlich prognostisch für einen Rückfall beim ER positive und HER2 negative eBC

Primele date cu ribociclib adjuvant

Eine Herausforderung für viele Patienten, wenig Doktoren

TILs sind prognostisch aber nicht prädiktiv beim HER2+ eBC

PHERGain abre la posibilidad de evitar la quimioterapia en el cáncer de mama HER2+

I miei punti salienti di ASCO23

TILs Subtypen sind assoziiert mit klinischen Merkmalen und Prognose beim HR+/HER2- BC

Czy wystarczy, aby zmienić standardy?

Kolejny dowód na skuteczność immunoterapii w zaawansowanym raku trójujemnym

1/3 der Patientinnen mit HER2+ zukünftig ohne Chemotherapie?

TILs w rakach HER2+ - znaczenie rokownicze, ale nie droga do deeskalacji leczenia

SOC der ovarialen Ablation in der Metaanalyse bestätigt

NATALEE nicht überraschend aber überzeugend positiv

Von PENELOPE-B zur SURVIVE

Eine Herausforderung für das klinische Management

Palbociclib después de Palbociclib podría no ser la mejor opción

Ovar Funktion - Ovarielle Supression verzichtbar bei jungen Patientinnen?

Chemo-IO Signale bei HER2low prädiktiv für Ansprechen der Chemotherapie

Response adaptierte, Chemotherapie-freie Option beim HER2+ eBC

CDK4/6 i beyond CDK4/6 i: one more piece to the puzzle

Molecular imaging for endocrine responsivness

E-Health Applications in Oral Cancer Therapy

Updates on ADCs in metastatic breast cancer

The start of precision medicine in HR+ breast cancer

What is the optimal therapie sequence for HR+ MBC patients?

Continued OS benefit for Sacituzumab Govitecan

Aggiornamenti sugli ADC nel carcinoma mammario metastatico

CDK4/6i dopo CDK4/6i, un altro pezzo del puzzle: lo studio PALMIRA

Mises à jour sur les ADC dans le cancer du sein métastatique

The value of eHealth

CDK4/6 Sequencing? ESR-1 not ready for prime time? Palbo rechallenge?

Update ADC efficacy

CDK4/6i in first line and beyond & Biomarkers

Part2: Important update on testosterone-recovery

Part 1: Important update on testosterone-recovery

TALAPRO-2: Results and controversies

Over-staging of bone scan compared with PSMA PET/CT

Confirming results for PARPi in mCRPC

Reassuring real-world data!

PSA nadir 6 month after Radiotherapy is strong prognostic marker for survival

Intensified or de-intensified therapy in mHSPC

AI for prediction in local prostate carcinoma

LuPARP combination study: LuPSMA and Olaparib in mCRPC

Metastasis-directed for prostate cancer

PAPR-inhibitors: Patient-selection matters!

ARASEC: ADT + Daralutamide for mHSPC

DEAR trial: real-world comparator analyses of ARIs

PEACE 1 - results and controversies

PRL-02: Intramuscular arbiraterone

PARP-inhibitors: La selección de pacientes es importante

LuPARP studien: 177-Lu-PSMA och olaparib vid mCRPC

Επιβεβαίωση αποτελεσμάτων για το PARPi στο mCRPC

Skelettscintigrafi ospecifikt jämfört med PSMA PET-CT

PSA nadir 6 månader efter radioterapi är en prognostisk markör för överlevnad

Intensifierad eller de-intensifierad behandling vid mHSPC?

PARPi in PCa: more genetic testing is required as PRO data demand better patient selection

Triple therapy in mCSPC - which is the ideal partner for radiotherapy? And which patients should received irradiation?

What is your preferred sequence in 1st line treatment and how you treat after progress?

Q-TWiST in the therapy of aUC

The beginning of a new era in urothelial cancer?!

Best of Bladder: ddMVC increases DFS! Standard dissection SOC? FGFR targeting showing efficacy!

New SoC option for metastatic bladder cancer

FGFR inhibition

First line in cisplatin-ineligible advance urothelial cancer: It´s getting busy out there

Enfortumab vedotin + pembrolizumab 1stL in cisplatin-ineligible patients

New standard for MIBC

Targeted therapies in advanced urothelial cancer: The renaissance?!

Extent of lymphadenectomy in cystectomy

Nouvelles options de soins standard pour le cancer de la vessie métastatique

Primera línea en cáncer urotelial avanzado no elegible para cisplatina: Hay mucho trabajo ahí fuera

Terapias dirigidas al cáncer urotelial avanzado: ¡¿El renacimiento?!

Best of Bladder: ddMVC increases DFS! Standard dissection SOC? FGFR targeting showing efficacy!

The efficacy of FGFR targeting

The efficacy of neo-adjuvant therapy (ddMVAC, Cisplatinum)

Update EV/Pembro, Avelumab Maintenance

Non ccRCC: how should we treat patients today?

Primary endpoint not reached: what do we learn from CONTACT-03 results?

Long term follow up in advanced renal cell cancer: Is everything clear, yet?

The impact of microbiome and supplements on therapy efficacy

1st Line therapy RCC: which combination to choose?

Lenvatinib + pembrolizumab in non-clear cell renal cell carcinoma

New data non ccRCC

Update and take home message of 1st Line mRCC

New standard for 2nd line RCC?

IO rechallenge in mRCC

News from the adjuvant

Long-term follow-up for IO/TKI in mRCC

ADAURA: Osimertinib improves survival in the treatment of EGFRm rNSCLC

The value of perioperative chemo-IO in rNSCLC and the importance of staging

Confirmation of neoadjuvant immunotherapy

ADAURA - results and controversies

Adjuvant and neoadjuvant strategies in resectable NSCLC

CheckMate 9LA: 4‑year clinical update

ADAURA - Discussion closed?

OS benefit from EGFR receptor TKI

Another neoadjuvant chemo/IO option

A chemo-free preop. IO strategy?

Added benefit of perioperative chemo/IO in stage 2-3b NSCLC

Perioperative treatment

Role of periopertative IO confirmed

An imperfect analysis, but perfect results

EGFR testing necessary in the adjuvant setting

Adjuvant IO in KRASm patients

A new standard of care

Which should we prefer: neoadjuvant, adjuvant or perioperative chemo/IO?

More options in the perioperative setting

A new standard of care for operated patients with eGFRmut adenocarcinoma

Induction options in the perioperative setting

Un nouveau standard therapeutique pour les patients opérés d’un adenocarcinome EGFR muté

ADAURA- discussie gesloten?

Más opciones en el entorno perioperatorio

Stratégies adjuvantes et néoadjuvantes dans le CBNPC résécable

Rolle der periopertativen IO bestätigt

Que devrions-nous préférer: traitement néoadjuvant, adjuvant ou chimio/IO périopératoire?

Toegevoegde waarde van periperatief chemo-immuno bij stadium II-IIIB NSCLC

Pembro + chemo in pts with TKI-resistant EGFRm / Sunvozertinib - a drug for Exon20 insertions

Sotorasib: clear clinical benefit, but short follow-up time

Zorifertinib: an option when osimertinib is not available

TTF-treatment requires further studies

Does ADC + chemo + IO replace the existing concepts?

Update on KRASG12Cm treatment options - how to proceed?

CORRELATE - a real world analysis

TROP2-ADC shows high response rates in 1L-combination therapy, but safety must be observed

Stopping treatment is ok

IO in EGRF positive patients post TKI

LUNAR: TTF medical device shows OS-benefit, but more information needed

ADC + ICI ± Pt-CT in patients with aNSCLC

Hyperfractionation - an interestingh concept, but not for every patient

New data from another BiTE

Treatment strategies in SCLC

More BiTEs, more possibilities

A positive trial with no impact

Can we incoporate biomarkers in SCLC treatment?

Hyperfractionated radiotherapy for SCLC

Kunnen we biomarkers gebruiken om behandeling te selecteren voor SCLC?

Más BiTEs, más posibilidades

Stratégies de traitement dans le SCLC

ONCOalert (inclusive patient advocates) consensus on the results of the PROspect trial

No practice-changing data in mesothelioma, other studies to await

Immune checkpoint inhibitors in malignant mesothelioma

Immun-Checkpoint-Inhibitoren beim malignen Mesotheliom